- Home
- ISPC vs SONN Comparison
ISPC vs SONN Comparison
Compare ISPC & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- SONN
- Stock Information
- Founded
- ISPC 2009
- SONN N/A
- Country
- ISPC United States
- SONN United States
- Employees
- ISPC N/A
- SONN N/A
- Industry
- ISPC Precision Instruments
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- ISPC Health Care
- SONN Health Care
- Exchange
- ISPC Nasdaq
- SONN Nasdaq
- Market Cap
- ISPC 3.2M
- SONN 3.8M
- IPO Year
- ISPC 2021
- SONN N/A
- Fundamental
- Price
- ISPC $1.26
- SONN $1.25
- Analyst Decision
- ISPC
- SONN Strong Buy
- Analyst Count
- ISPC 0
- SONN 1
- Target Price
- ISPC N/A
- SONN $20.00
- AVG Volume (30 Days)
- ISPC 37.6K
- SONN 39.8K
- Earning Date
- ISPC 08-05-2025
- SONN 05-13-2025
- Dividend Yield
- ISPC N/A
- SONN N/A
- EPS Growth
- ISPC N/A
- SONN N/A
- EPS
- ISPC N/A
- SONN N/A
- Revenue
- ISPC $8,058,631.00
- SONN $1,000,000.00
- Revenue This Year
- ISPC $35.93
- SONN $5,376.22
- Revenue Next Year
- ISPC N/A
- SONN N/A
- P/E Ratio
- ISPC N/A
- SONN N/A
- Revenue Growth
- ISPC N/A
- SONN 978.39
- 52 Week Low
- ISPC $1.02
- SONN $1.08
- 52 Week High
- ISPC $11.80
- SONN $16.00
- Technical
- Relative Strength Index (RSI)
- ISPC 55.51
- SONN 51.70
- Support Level
- ISPC $1.15
- SONN $1.13
- Resistance Level
- ISPC $1.29
- SONN $1.21
- Average True Range (ATR)
- ISPC 0.08
- SONN 0.08
- MACD
- ISPC 0.02
- SONN 0.00
- Stochastic Oscillator
- ISPC 75.00
- SONN 56.67
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.